Key points from article :
Immetas Therapeutics and GC Biopharma have teamed up to develop novel mRNA therapeutics for autoimmune diseases.
This partnership combines GC Biopharma’s mRNA therapeutic and lipid nanoparticle (LNP) delivery platforms with Immetas' expertise in modulating immune pathways. GC Biopharma, based in Yongin, South Korea, has been actively researching mRNA therapeutics since 2017. Their role in this collaboration involves designing mRNA constructs and selecting suitable LNP formulations for delivery, as outlined in their recent press release.
Immetas, headquartered in New Jersey, specializes in developing treatments for chronic inflammation-driven diseases. In this collaboration, Immetas will focus on identifying therapeutic targets and generating payload molecules that can help in developing new treatments for autoimmune diseases. The combined efforts of both companies aim to accelerate the discovery and development of effective therapies.
GC Biopharma, formerly known as Green Cross Corporation, has an established clinical development pipeline across various disease areas. Recently, the company achieved a major milestone with FDA orphan drug designation for its Thrombotic Thrombocytopenic Purpura (TTP) drug candidate, GC1126A. This new mRNA collaboration reflects their ongoing efforts to expand their therapeutic offerings.
The collaboration also comes at a time when the biopharmaceutical industry is increasingly focusing on mRNA therapeutics. This shift was driven by the successful development of mRNA-based COVID-19 vaccines, a breakthrough supported by the research of Nobel Prize winners Katalin Karikó and Drew Weissman.
As mRNA technology continues to gain traction, it is expected to revolutionize treatments for various diseases, including autoimmune disorders, cancer, and viral infections. The partnership between Immetas and GC Biopharma could contribute to this growing field, bringing new hope to patients with autoimmune conditions.
